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Coordinated autophagy 
modulation overcomes 
glioblastoma chemoresistance 
through disruption of 
mitochondrial bioenergetics
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Edward Ojuka3, Bert Klumperman4 & Ben Loos1
Glioblastoma Multiforme (GBM) is known to be one of the most malignant and aggressive forms 
of brain cancer due to its resistance to chemotherapy. Recently, GBM was found to not only utilise 
both oxidative phosphorylation (OXPHOS) and aerobic glycolysis, but also depend on the bulk 
protein degradation system known as macroautophagy to uphold proliferation. Although autophagy 
modulators hold great potential as adjuvants to chemotherapy, the degree of upregulation or 
inhibition necessary to achieve cell death sensitisation remains unknown. Therefore, this study aimed 
to determine the degree of autophagy modulation necessary to impair mitochondrial bioenergetics to 
the extent of promoting cell death onset. It was shown that coordinated upregulation of autophagy 
followed by its inhibition prior to chemotherapy decreased electron transfer system (ETS) and oxidative 
phosphorylation (OXPHOS) capacity, impaired mitochondrial fission and fusion dynamics and enhanced 
apoptotic cell death onset in terms of cleaved caspase 3 and cleaved PARP expression. Therefore, 
coordinated autophagy modulation may present a favourable avenue for improved chemotherapeutic 
intervention in the future.
Globally, Glioblastoma Multiforme (GBM) presents as both the most prevalent and invasive form of Central 
Nervous System (CNS) malignancy. Patient life expectancy has remained largely unchanged over the past three 
decades, with a mean survival time of only 15 months1. This has been attributed to the rapid tumour recurrence 
and resistance to cell death after exposure to chemotherapy, radiation and surgical removal. Initial attempts to 
identify the key genetic markers associated with resistance led to the identification of enhanced DNA repair 
through MGMT mediated signalling in highly malignant tumours2. Cell cycle and angiogenesis related molecular 
regulators such as AKT, PTEN and Ras have also shown to be frequently mutated in these tumours3. However, 
combining growth factor receptor inhibitors or anti-angiogenic reagents with chemotherapy has not been able to 
enhance mean patient survival time4. Furthermore, excessive exposure to chemotherapy and radiation has been 
shown to decrease patient quality of life following treatment, contributing to decreased patient survival time4.
This has led to a resurgence in studies focussing on the metabolic upkeep of GBM pathogenesis and resist-
ance5. The involvement of macro-autophagy (hereafter referred to as autophagy) in upholding healthy cell 
metabolism under nutrient limiting conditions has garnered much interest with regards to its role in tumour 
bioenergetics6. Mammalian target of rapamycin (MTOR) dependent induction of autophagy results in the bulk 
degradation of long lived or damaged cytosolic proteins and organelles. This provides key metabolic substrates 
for glycolysis and the tricarboxylic acid (TCA) cycle, thereby making it an excellent energy reservoir to uphold 
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tumour proliferation under hypoxic or cytotoxic conditions7. In this regard, autophagy induction has been 
observed in response to treatment of glioma cells with the standard of care chemotherapeutic Temozolomide 
(TMZ)8. However, given the molecular crosstalk between regulators of apoptosis and autophagy, enhanced GBM 
cell death onset has been observed in recent studies combining either autophagy inducers (such as Rapamycin or 
Temsirilomus) or inhibitors (such as Hydroxychloroquine or Bafilomycin) with chemotherapy9,10. Furthermore, 
current phase 1 clinical trials focussing on the adjuvant effects of such modulators in chemotherapy pay little 
attention to the involvement of autophagy in key metabolic pathways.
Current evidence suggests that both oxidative and glycolytic metabolic pathways are involved in glioma pro-
gression, depending on their level of malignancy11–13. In the context of chemotherapeutic resistance, glioma cells 
have been shown to depend on enhanced electron transport system (ETS) coupling and autophagy to acquire 
resistance to TMZ10,14–16. The mitochondrial network operates as a highly energetic reticulum subjected to con-
tinuous and rapid remodelling through fission and fusion events. Although evidence exists for the involvement 
of the fission and fusion machinery in metabolic sensing and ETC efficiency, their role in tumour metabolism 
remains unclear17,18. Therefore, this study aimed to: (i) determine the degree of autophagy modulation necessary 
to sensitise glioma cells to chemotherapy; (ii) assess mitochondrial bioenergetics in terms of topology, fission and 
fusion dynamics and electron transport system efficiency; (iii) assess whether changes in autophagic flux results 
in an altered mitochondrial bioenergetic phenotype and (iv) determine the extent of diminished mitochondrial 
bioenergetic capacity necessary to achieve cell death sensitisation.
Materials and Methods
Cell Culture. U-118MG and U-87 cells were purchased from the American Type Culture Collection (ATCC) 
and supplemented with Dulbecco’s Modified Eagles Medium (DMEM), 1% penicillin/streptomycin (PenStrep) 
(Life Technologies, 41965062 and 15140122) and 10% foetal bovine serum (FBS) (Scientific Group, BC/50615-HI) 
and incubated in a humidified incubator (SL SHEL LAB CO2 Humidified Incubator) in the presence of 5% CO2 at 
37 °C. 3D spheroids were generated by coating 96 well plates with 50 µl of 0.1% agarose solution per well, leaving 
the agarose to solidify under UV light 1 hour prior to seeding (2 × 103 cells per well). Spheroids were incubated 
for a maximum of 72 hours prior to treatment.
Reagents. The autophagy modulating drugs, Hydroxychloroquine Sulfate (HCQ) and Rapamycin, as well as 
the chemotherapeutic Temozolomide (TMZ) were purchased from Sigma-Aldrich (1327000, R8781 and T2577). 
Bafilomycin A1 was acquired from LKT laboratories (B0025). HCQ and Bafilomycin A1 were dissolved in H20, 
whist Rapamycin and TMZ were prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, D2650). Primary 
antibodies for LC3, cleaved-Caspase3, cleaved-PARP and β-Actin were obtained from Cell Signalling (2775, 
9541 S, 56416, 4970). ATG5 primary antibody was obtained from Santa Cruz (sc-8666) and TOMM-20 from 
abcam (ab56783). The mitochondrial primary antibodies OPA-1, Drp1, MFN-1, MFN-2 and secondary antibod-
ies (anti-rabbit, anti-mouse and anti-goat) were purchased from Abcam (ab157457, ab56788, ab57602, ab56889, 
ab78547, ab97110). All compounds for the mitochondrial respiration medium (MiRO5) were purchased from 
Sigma-Aldrich unless otherwise specified. MiRO5 medium consisted of EGTA (E4378), MgCl2 (M8266), 
Lactobionic acid (153516), Taurine (T0625), KH2P04 (Merck, 104873), HEPES (H7523), D-Sucrose (84097) and 
BSA (10735078001). The substrates, uncouplers and inhibitors used during the SUIT protocol were supplied 
by Sigma-Aldrich, including L-Glutamic acid (G1626), L-Malic acid (M1000), Pyruvic acid (P2256), Succinate 
(S2378), Ascorbate (A4034), Tetramethyl-p-phenylenediamine dihydrochloride (TMPD, T3134), Adenosine 
5’diphosphate (ADP, A2754), Carbonyl cyanide m-chloro phenyl hydrazine (CCCP, C2759) and Antimycin A 
(A8674). Cell permeabilization was achieved through titration of Digitonin (D141, 10 mg dissolved in 1 mL 
DMSO).
Synthesized Polymer. Nanocarriers were prepared via self-assembly of block copolymers consist-
ing of polyethylene glycol (PEG) as the hydrophilic block and the polypeptide as hydrophobic block. The 
self-assembly into micellar aggregates typically results from interactions with the bioactive molecules or 
induced by a pH change19–21. Bioactive molecules are normally bound to or adsorbed in the core through 
physical interactions such as hydrophobic interactions or electrostatic interactions22,23. A novel nano car-
rier was prepared by covalently attaching hydroxychloroquine via an acid-labile β-thiopropionate bond to 
poly(N-vinylpyrrolidone-block-(cysteine-co-glycine)).
Cell Viability Assays. Mitochondrial reductive capacity was used as an indicator for cell viability, and meas-
ured using water-soluble tetrazolium bromide (WST-1) (Roche, 11644807001). Cells were seeded in 48-well 
plates, where after cell culture media containing treatment reagents was aspirated and replaced with 200uL of 
fresh media. 5 uL of WST-1 was added to each well and incubated at 37 °C for 80 minutes, after which the 48-well 
plate was placed in a multiplate reader (EL-800, Bio-Tek instruments Inc.) and absorbance values read at 480 nm. 
Reductive capacity was calculated in percentage relative to the untreated control group. Apoptosis was further 
quantified by propidium iodide (PI) exclusion assays using flow cytometry (BD FACS Aria). Prior to cell sorting, 
treated cells were trypsinized, centrifuged (1100 rpm, 3 min) and resuspended in PI staining solution (2ug/mL 
diluted in PBS) for 15 minutes. Analysis was conducted using FACS Diva software. Spheroids were stained with PI 
for 1 hour prior to imaging and viability was measured as the mean fluorescence intensity using ImageJ (version 
1.51, National Institutes of Health, USA).
Transfection. Cells were transfected with mitochondrial associated photoactivatable green fluorescent pro-
tein (mito-PA-GFP) or ATG siRNA (Hs_APG5L_5 FlexiTube siRNA, Qiagen, NM_004849) through electropora-
tion utilizing the Neon® Transfection System (Life Technologies). Transient transfection was achieved as per the 
manufacturers guidelines at a final voltage of 1300 V, 30 ms pulse width and cell density of 5 × 105.
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Confocal Microscopy. Photoactivation Assay. In order to determine the rate at which mitochondrial fis-
sion and fusion occurs, the spread of mito-PA-GFP from a subset of mitochondria throughout the mitochon-
drial network was tracked over time, as previously described by Karbowski et al. (2004), using a Carl Zeiss 
Confocal Elyra PS1 microscope with LSM 780 technology24. Transfection with mito-PA-GFP and staining with 
tetramethylrhodamine-ethyl ester (TMRE) (Life Technologies, T669) allowed for visualisation of the mitochon-
drial network. Following transfection, cells were treated accordingly and stained with 100 nM TMRE. For each 
cell, 2–3 regions of interest (ROI) of the cross-section area in a single focal plane was selected for photoactivation. 
Once selected, these regions were exposed to 403 nm laser stimulation at 100% intensity, resulting in the activa-
tion of mito-PA-GFP observed at 60× magnification. Only regions that displayed an increase in signal intensity 
of at least twice that of the initial intensity were tracked over time. Mito-PA-GFP signal distribution was observed 
under 488 nm excitation and a live cell time lapse was constructed with images acquired every second for 300 
cycles (10 minutes) using an iteration speed of 15. Image processing was conducted with ZEN software (black 
edition, 2011, version 7.04.287). A detailed example of signal decay resulting from individual fission and fusion 
events is illustrated in Supplementary Fig. 1.
Morphometrics. To assess the morphometric characteristics of mitochondrial networks, live cell confocal 
microscopy was conducted with z-stacks acquired every 30 seconds for 10 minutes (Carl Zeiss LSM 780) in order 
to produce mean intensity projections for image analysis. Prior to imaging, media was removed followed by treat-
ment with 200 μL TMRE working solution. Image processing was conducted in Wolfram Mathematica (Version 
10.2) to generate graph-like binarized micrographs. These were used to assess the degree of connectivity within 
the mitochondrial networks (calculated as the total number of vertices by the total number of overlapping ver-
tices within a graph like structure) and to determine the degree of scaling (given by a linear gradient fitted to 
a log[Area] log[Perimeter] scatter plot. Spheroid size determination was conducted prior to live cell imaging 
(Olympus IX81 widefield microscope) with ImageJ (version 1.51, National Institutes of Health, USA).
Western Blot Analysis. Total cell protein was extracted utilising a modified radio immunoprecip-
itation (RIPA) buffer consisting of 20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 10% Nonidet-P40 and 10% 
Na-deoxycholate, 42 µL complete EDTA-free protease inhibitor tablet solution, 1 mM PMSF, 1 mM Na3VO4 and 
1 mM NaF phosphatase inhibitors. Protein concentration was determined using a Bradford Assay25. Cell lysates 
were diluted in Laemmeli sample buffer, boiled for 5 min and 50 µg protein was separated by 12% SDS-PAGE-gel 
electrophoresis (Bio Rad Mini-Protean ®TGX™ fast cast system). Proteins were transferred onto a PVDF (poly 
vinydilene difluoride) membrane using BIO-RAD Trans-Blot transfer packs and a BIO-RAD Trans-Blot turbo 
transfer system. Membranes were blocked for 60 minutes in 5% non-fat milk made up in 1 × TBS-T (Tris-buffered 
saline and 1% Tween20), followed by incubation with appropriate primary and secondary anti-bodies. Band 
intensities were detected with a BIO-RAD Chemidoc MP imaging system using Image Lab software (version 4.1) 
and expressed as a percentage relative to band intensities of untreated control cells. β-actin was used as a loading 
control for all membranes.
Bafilomycin A1 Treatment for Western Blot Analysis of LC3. Bafilomycin A1 impairs the fusion of 
lysosomes with autophagosomes by inhibiting H+ATP-ase activity. A 100 µM stock solution was prepared in 
DMSO and diluted to 400 nM in normal growth media. Cells were seeded in 25 cm2 flasks at a density of 10 × 106 
cells and treated accordingly, followed by incubation with 400 nM Bafilomycin 4 hours prior to protein extraction. 
RIPA protein extraction, Braford analysis, sample preparation and Western Blot analysis of LC3 and β-Actin was 
performed as described above.
High resolution respirometry. Measurement of mitochondrial respiration was performed with a polaro-
graphic oxygen sensor in 2 ml glass chambers of an Oxygraph 2 K (Oroboros Instruments, Innsbruck, Austria). 
The amplified signal from the oxygen sensor was recorded on a computer at sampling intervals of 2 sec using 
DatLab acquisition software (Oroboros Instruments, Innsbruck, Austria). Before all experiments were com-
menced, calibration of the respirometer was performed at air saturation, 37 °C. The electron transfer system (ETS) 
and oxidative phosphorylation (OXPHOS) capacities were determined through stepwise titration of specific sub-
strates and inhibitors (SUIT protocol). In accordance with the Oroboros guidelines (Gnaiger, 2014), the result-
ing O2 flux values were utilized to calculate routine respiration, the non-phosphorylating resting state (LEAK), 
OXPHOS capacity through complex 1, residual oxygen consumption (ROX) and complex IV activity for nor-
malisation. Following permeabilization with 1.5 mM Digitonin, Pyruvate (5 mM), Malate (2 mM) and Glutamate 
(10 mM) were added to determine the LEAK state. Complex I linked OXPHOS was measured by addition of 
2.5 mM ADP. ETS capacity was determined through subsequent titrations of 0.5 µM CCCP, until a maximal oxy-
gen flux was reached, which was taken as the maximal ETS capacity. Correcting for ROX, involved the addition 
of complex III inhibitor Antimycin-A and the resulting flux was subtracted from all final values. Complex IV 
activity was used as a surrogate marker for mitochondrial number, and therefore subtracted from all the final 
ETS and OXPHOS capacities26. To achieve this, titration of TMPD (0.5 mM) and ascorbate (2 mM) to assess 
complex-IV-linked respiration was performed as a proxy for mitochondrial content. Oxygen flux at all respiratory 
states was normalized to the complex-IV flux to correct for variations in cell content in the oxygraph chambers.
Lactate Determination. U-118MG cells were seeded in 6- well plates at a density of 10 × x 105 cells per 
well. After treatment, 2 mL of culture medium was used for lactate determination. Lactate determination required 
addition of 5 µl sample or lactate standard (0–5 mM) to 95 µl PBS (1 mM), NAD + (4 mM), LDH (4 U/mL) and 
hydrazine (320 mM) in a 96-well plate, incubated for 90 minutes at 37 °C. Absorbance values were read at 340 nm 
using a BioTek Powerwave 340 spectrophotometer.
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Statistical Analysis. All statistics were conducted in Statistica (13.0) utilising a one-way ANOVA together 
with Bonferonni and LSD Post-Hoc Tests where p < 0.05 was considered significant.
Data availability. The datasets analysed in the current study are available from the corresponding author on 
reasonable request.
Decreased cell viability is associated with decreased autophagic flux. WST-1 viability assays were 
conducted to assess the effects of autophagy modulators (HCQ and Rapamycin) as well as TMZ on cell viability, 
represented by the percentage mitochondrial reductive capacity. Incubation of glioma cells for with the autophagy 
inducer Rapamcyin (50 nM, 6 hours) led to a significant increase in reductive capacity (Fig. 1a). Conversely, treat-
ment with HCQ (50 µM) for the same duration decreased cell viability (Fig. 1a) and incubation for 24 hours 
with TMZ (250 µM) led to a moderate decrease in reductive capacity (Fig. 1a) when compared to the untreated 
control. This indicates that although the U-118MG cell line was sensitive to chemotherapy, failure to reach more 
than a 50% decrease in reductive capacity after prolonged incubation made it possible to investigate the sensiti-
sation effects of adjuvant treatments. Two adjuvant treatment groups were investigated. The first was incubation 
of 50 µM HCQ for 6 hours followed by 250 µM TMZ for 24 hours (HT). The second group consisted of 6 hours 
Rapamycin pre-treatment, followed by incubation of 50 µM HCQ and 250 µM TMZ for and 24 hours respectively 
(RHT) (Fig. 1a).
HT treatment decreased reductive capacity significantly when compared to the control, although no signifi-
cant difference was observed in comparison to TMZ treatment (Fig. 1a). However, dual modulation through RHT 
treatment proved to have the most prominent effect, with a substantial decrease in reductive capacity observed 
when compared to both individual modulation groups and the TMZ group (Fig. 1a). Of note, dual modulation 
led to a decrease in the percentage reductive capacity, which was of the same level as that of cells treated for 
48 hours with TMZ (500 µM) (Supplementary Fig. 2). Furthermore, this sensitization effect was achieved through 
the use of Rapamycin and HCQ concentrations which were not inherently highly toxic to glioma cells in vitro. 
Seeing as many clinical trials currently focus on the adjuvant use of HCQ with chemotherapy, the HCQ adjuvant 
group was selected in addition to the dual modulation group for further analyses.
Inhibition of lysosomal fusion through BafilomycinA1 (Baf) treatment results in the accumulation of auto-
phagosomal vacuoles, which can be measured by quantifying the relative levels of LC3-II protein present in the 
cell lysate. Quantifying the change in LC3-II in the presence and absence of Baf (400 nM) indicates the relative 
amount of autophagosome production present in a population of cells, serving as an indicator of the rate of 
protein degradation through autophagy i.e. autophagic flux. Significantly increased LC3-II protein levels were 
observed for the Baf positive Control, Rapamycin and TMZ groups when compared to their corresponding Baf 
negative expression levels, representative of an increased autophagic flux following Rapamycin and TMZ treat-
ment (Fig. 1b–d). No significant increase was observed in the presence of Baf for the HCQ, HT and RHT groups 
when compared to their Baf untreated LC3-II expression levels, which suggests that autophagosome degradation 
was impaired (Fig. 1b–d).
Figure 1. Decreased cell viability is associated with decreased autophagic flux. (a) WST1 viability assay, (b) 
Relative protein expression levels of LC3 and corresponding representative immunoblots in the presence and 
absence of Bafilomycin (Baf) treatment (400 nM, 2 hours) for (c) Control, 50 nM Rapamycin (Rapa), 50 µM 
Hydroxychloroquine (HCQ) and 250 µM Temozolomide (TMZ) and (d) Control, 250 µM TMZ, treatment HCQ 
(50 µM) + TMZ (250 µM) (HT) and Rapa (50 nM) + HCQ (50 µM) + TMZ (250 µM) (RHT) treatment groups. 
All error bars, ±SEM. ***p < 0.001, *p < 0.05 vs Control n = 6, #p < 0.05 vs corresponding Baf negative group 
n = 3.
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Given that LC3-II is a reliable marker for autophagosome production, our data shows that an accumulation of 
LC3-II (decreased autophagic flux) is associated with diminished cell viability.
Autophagy modulation, chemotherapy and its combination disrupts mitochondrial fission 
and fusion dynamics. Next, we assessed whether changes in autophagic flux is associated with an altered 
mitochondrial phenotype. The potential of mitochondrial subunits to fuse with one another has been shown 
to correlate with healthy mitochondrial functionality. Therefore, we quantified the rate at which mitochondrial 
mitochondrial fission and fusion occurs for each treatment group, given by the decay in signal intensity of acti-
vated mito-PA-GFP over time. Fluorescence intensity was measured every second for 600 seconds and plotted 
over time as the percentage of initial signal intensity post activation (Fig. 2).
Linear regression through signal decay curves indicated that the fastest signal dissipation rate was displayed 
by Control cells and those treated with Rapamycin, indicating functional fission and fusion as the percentage 
fluorescence intensity reached below 50% after 300 seconds (Fig. 2a–c). However, signal dissipation rate was sig-
nificantly impaired in the TMZ and RHT groups with a 50% decrease only observed after the full and 600 second 
time lapse suggesting that mitochondrial fission and fusion was impaired (Fig. 2b,c). Of note, although a large 
degree of fragmentation was observed in the HCQ, HT and RHT groups, the same decay curve was obtained for 
the intermediately fragmented network of the TMZ group (Fig. 2, Supplementary Fig. 2). Impaired fusion capa-
bility was therefore shown for treatment groups that displayed both impaired (HCQ, HT and RHT) and enhanced 
(TMZ) autophagic degradation. To rule out cell line specificity, TMZ and RHT treatments were carried out on 
U-87 cells, which also presented with slower mito-PA-GFP signal dissipation rate in response to these treatments 
(Fig. 2e).
To ascertain whether these changes can be attributed to autophagic signalling, photoactivation was also 
performed on ATG5 siRNA knockdown cells. Conflicting evidence exists for the effect of ATG5 knockdowns 
Figure 2. Autophagy modulation impairs mitochondrial dynamics. Representative images of mito-PA-GFP 
transfected cells (60× magnification, scalebar 5 μM) with the activated region outlined in red enhanced to 
display lookup table (LUT, linear range) intensities at 0, 1, 5 and 10 minute intervals post activation for (a) U-87 
cells and (b) U-118 MG cells treated with TMZ, HT and RHT for both wild-type (WT) and ATG5 knockdown 
(KD) conditions. Mito-PA-GFP signal decay over time is represented as a percentage of the initial signal 
intensity in (c) and (d) for each cell line with corresponding slope comparisons of linear regressions through 
signal decay curves shown in (e) and (f). N = 6 *p < 0.05 vs control. (g) Representative immunoblot conducted 
to confirm ATG5 knockdown.
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on mitochondrial network morphology, as decreased and increased tubulation has been reported in separate 
studies27,28. However, ATG5 has been implicated in mitochondrial quality control possibly through regulating 
mitophagy29. Therefore, even though structural changes might not be apparent, it is possible that functional 
responses in knockdown cells will be different. Indeed, our data indicate that the signal dissipation rate of acti-
vated mito-PA-GFP is slower in ATG5 siRNA knockdown U-87 and U-118 cells than in their wild type counter-
parts (Fig. 2,e,f). Furthermore, the fision and fusion response to both TMZ and RHT treatment was also altered, 
with a further decrease in signal dissipation rate observed for TMZ and RHT treated ATG5 knockdown cells 
that in their wild-type counterparts. These data indicate that complete inhibition of autophagy results in abrupt 
changes in mitochondrial dynamics and that the altered signal dissipation rate observed in the TMZ and RHT 
groups can be attributed to changes in autophagic flux.
Coordinated autophagy modulation impairs mitochondrial network connectivity. In order to 
relate mitochondrial network dynamics to their topology, the connectivity between mitochondrial subunits was 
quantified in terms of the degree of scaling within these networks and the amount of overlap between membrane 
structures. Scaling invariance was calculated by fitting a power law relationship to scatter plots of the outer perim-
eter and inner area of each network cluster (Fig. 3). With regards to the pure network properties of the mitochon-
drial networks the ratio of the total number of vertices to the number of connected clusters for a given graph was 
assessed, providing a “connectivity index” (Fig. 3).
The mitochondrial networks of U-118MG cells under control conditions were found to be highly connected 
(Fig. 3). Less individual clusters were found for the Rapamycin treatment group, although the overall connectivity 
was unaltered (Fig. 3). HCQ treatment resulted in a significant increase in fragmentation, with a large number 
of unconnected clusters (Fig. 3). Significantly more clusters were also observed in cells treated with, which were 
considerably less connected than the control. HCQ pre-treatment followed by incubation with TMZ led to a 
decreased cluster count, with networks being significantly more connected than the TMZ treatment group, but 
less than the control (Fig. 3). Rapamycin pre-treatment followed by HT decreased the number of mitochondrial 
network clusters significantly, although they displayed the same intermediate degree of connectivity as that of the 
HT group.
Comparing the degree of scale invariance, a power law relationship was present for all treatment groups in 
terms of their area and perimeter measurements (Fig. 3c). Importantly, the RHT group yielded a larger power 
law relationship of 0.95 ( ± 0.0061), suggesting a more equal distribution of large and connected clusters (Fig. 3b). 
Of note, the HCQ (0.78 ± 0.018) and TMZ (0.80 ± 0.005) networks presented with the lowest gradients (Fig. 3c), 
indicative of smaller area and perimeter values due to the large amount of fragmentation.
Figure 3. Coordinated autophagy modulation impairs mitochondrial network connectivity. (a) Maximal 
intensity projections of glioma cells stained with TMRE (red) at 60× magnification (scale bar 5 μM), (b) Mean 
gradients of power law curve fittings and (c) Connectivity Index (Vertex Count/Cluster Count, CI) values 
for Control (C), Rapamycin (R), Hydroxychloroquine (HCQ), Temozolomide (TMZ), HCQ and TMZ in 
combination (HT) and Rapamycin, HCQ and TMZ in combination (RHT) treatment groups. N = 6, *p < 0.05.
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Chemotherapeutic resistance is associated with complex 1 linked OXPHOS and is diminished 
through coordinated autophagy modulation. A bioenergetic profile comprising of key metabolic states 
was generated following a SUIT protocol that was applied to permeabilised U-118MG cells and assessed through 
high resolution respirometry. Routine respiration and ETS capacity was not altered significantly by autophagy 
induction (Rapamycin, 50 nM), autophagy inhibition (HCQ, 50 µM) or treatment with chemotherapy (TMZ, 
250 µM) compared to control cells (Fig. 4a,b). However, HT treatment, as well as Rapamycin pre-treatment in 
combination with HT (RHT) decreased the maximal ETS capacity in comparison to both the control and TMZ 
treatment groups (Fig. 4b). Complex I linked OXPHOS was unperturbed by treatment with Rapamycin and HCQ 
(Fig. 4c), yet it was significantly enhanced following 24 hours incubation with TMZ and it decreased back to the 
same level as the control following pre-treatment with HCQ (Fig. 4c). Following the RHT regimen resulted in a 
significant decrease in complex I linked OXPHOS compared to Control, TMZ and HT treatment groups (Fig. 4c). 
From this, it can be deduced that OXPHOS through complex 1 is necessary to maintain mitochondrial respiration 
under chemotherapeutic conditions and that this response can be diminished through coordinated autophagy 
modulation.
Autophagy modulation in combination with TMZ decreased lactate production. In order to 
assess anaerobic glycolysis, the concentration of lactate produced per microgram protein was determined in 
culture media. Under control conditions, lactate production was measured at 30 µM/µg (±3.11 µM/µg), which 
remained unaltered after upregulation of autophagy with Rapamycin (50 nM), inhibition with HCQ (50 µM) 
and treatment with TMZ (250 µM) for 24 hours (Fig. 4d). Pre-treatment with HCQ (HT) and Rapamycin (RHT) 
decreased lactate production significantly to 18.95 µM/µg (±4.03 µM/µg vs Control p < 0.05) and 16.31 µM/µg 
(±2.47 µM/µg vs Control, p < 0.05) (Fig. 4d). Given that OXPHOS was also decreased in these groups, decreased 
autophagic activity seemed to impair both aerobic and anaerobic glycolytic pathways.
Mitochondrial Form and Function. Correlating O2 flux with Connectivity Index data indicates that 
although the HCQ and TMZ groups presented with the least amount of connectivity, their OXPHOS (Fig. 5a) 
associated respiration was above that of healthy control cells. Importantly, the two intermediately connected 
groups HT and RHT produced the least effective ETS response (Fig. 5b). These data suggest that attributing 
bioenergetic efficiency to morphological changes in isolation of respiratory analysis can be misleading and may 
mask the true cellular stress response.
Decreased expression of MFN1, MFN2, OPA1 and DRP1 is caused by coordinated autophagy 
modulation. In order to determine the molecular mechanisms responsible for the changes in dynamics and 
morphology observed in sections 3.2 and 3.3, the expression of key fusion and fission proteins was assessed 
through Western Blot analyses. These include the fusion proteins MFN1, MFN2 and OPA-1 as well as the fis-
sion protein DRP1. MFN1 protein levels remained unaltered following Rapamycin, HCQ and TMZ treatment 
(Fig. 6a,e). Pre-treatment with HCQ for 6 hours also had no effect on MFN1 expression (Fig. 6a,e). However, 
Figure 4. Chemotherapeutic resistance is mediated by complex 1 linked OXPHOS and is diminished through 
coordinated autophagy modulation. (a) Routine (b) Maximal ETS response and (c) OXPHOS through Complex 
I associated O2 Flux values and (d) concentration of lactate in growth medium, (e) correlation of O2 flux with 
Connectivity Index for all groups of interest for (e) OXPHOS through Complex I and (f) ETS Capacity for 
Control, 50 nM Rapamycin (Rapa), 50 µM Hydroxychloroquine (HCQ), 250 µM Temozolomide (TMZ), HCQ 
(50 µM) + TMZ (250 µM) (HT) and Rapa (50 nM) + HCQ (50 µM) + TMZ (250 µM) (RHT) treatment groups. 
All error bars, ±SEM. *p < 0.05, n = 3.
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6 hour pre-treatment with Rapamycin followed by HCQ and TMZ decreased MFN1 expression significantly com-
pared to the control (Fig. 6a,e).
MFN2 expression levels followed much the same trend as MFN1, with unaltered signal intensities observed 
for Rapamycin, HCQ, TMZ and HT treatment groups (Fig. 6b,e). A moderate, yet significant decrease in MFN2 
expression was observed after RHT treatment compared to control cells (Fig. 6b). Autophagy induction through 
Rapamycin did not alter OPA-1 expression levels, nor did inhibition through CQ (Fig. 6c). However, 24 hours of 
TMZ (250 µM) treatment decreased OPA-1 protein levels significantly compared to Control, with the same effect 
observed for the HT (HCQ pre-treatment) group (Fig. 6c). Upregulating autophagy for 6 hours (Rapamycin, 
50 nM) prior to incubation with HCQ (50 µM) and treatment with TMZ (250 µM) decreased OPA-1 expression 
considerably compared to both the control and TMZ groups (Fig. 6c), suggesting that both inner and outer mem-
brane fusion was impaired.
Figure 5. Decreased expression of MFN1, MFN2, OPA1 and DRP1 is caused by coordinated autophagy 
modulation. Relative protein expression levels of (a) MFN1, (b) MFN2, (c) OPA1 and (d) DRP1 in U-118MG 
cells. (e) Representative Immunoblot of relative Mitofusin 1 (MFN1) protein levels for Control, 50 nM 
Rapamycin (Rapa), 50 µM Hydroxychloroquine (HCQ), 250 µM Temozolomide (TMZ), HCQ (50uM) + TMZ 
(250 µM) (HTMZ) and Rapa (50 nM) + HCQ (50 µM) + TMZ (250 µM) (RHT) treatment groups. N = 3. 
*p < 0.05.
Figure 6. Cell death induction is only apparent in the RHT treatment group of U-118MG cells. (a) Relative 
protein expression levels of cleaved PARP. (b) Relative protein expression levels of cleaved Caspase 3. (c) 
Representative Immunoblot of relative cleaved PARP and cleaved caspase-3 expression levels for Control, 50 nM 
Rapamycin (Rapa), 50 µM Hydroxychloroquine (HCQ), 250 µM Temozolomide (TMZ), HCQ (50 µM) + TMZ 
(250 µM) (HT) and Rapa (50 nM) + HCQ (50 µM) + TMZ (250 µM) (RHT) treatment groups. N = 3, *p < 0.05 
vs corresponding Baf negative group. N = 3. *p < 0.05, ***p < 0.001.
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Induction of autophagy for 6 hours with Rapamycin did not alter DRP1 protein expression, nor did 6 hours 
of autophagy inhibition with HCQ (Fig. 6d). The same was observed following 24 hours incubation with TMZ 
(250 µM) and 6 hours co-incubation with HCQ (Fig. 6d). However, RHT treatment decreased DRP1 expression 
significantly compared to the control (Fig. 6d,e), which indicates that regulation of both key fission and fusion 
proteins was impaired in the RHT group which displayed lowest mitochondrial respiratory activity.
Apoptotic Cell death induction is only apparent in the RHT treatment group. Cleavage of caspase 
3 is a result of apoptosis induction through the intrinsic pathway and results in cleavage of the DNA repair 
enzyme PARP. Cleavage of PARP renders it incapable to counter act DNA damage, the accumulation of which 
results in cell death onset. Relatively unaltered cleaved caspase-3 expression was observed for Rapamycin and 
HCQ treatment groups (Fig. 7a,c). Cleaved caspase-3 protein levels were diminished following 6 hours incuba-
tion HCQ (Fig. 7a,c). HCQ pre-treatment (50 µM, 6 hours) followed by TMZ (250 µM, 24 hours) also decreased 
cleaved caspase 3 protein levels. However, inducing autophagy with Rapamycin (50 nM) 6 hours prior to incu-
bation with HCQ (50 µM, 6 hours) and TMZ (250 µM, 24 hours) resulted in significantly increased cleaved 
caspase-3 protein levels (Fig. 7a,c). Cleaved-PARP protein levels were unaltered when upregulating autophagy 
with Rapamycin (50 nM) as well as after inhibition of autophagy with HCQ (Fig. 7b,c). 24 hours incubation with 
TMZ also did not alter cleaved-PARP expression. However, co-incubation of HCQ with TMZ for 6 hours signif-
icantly enhanced cleaved-PARP expression (Fig. 7b,c). Pre-treatment with Rapamycin, followed by HCQ and 
TMZ treatment also increased cleaved-PARP protein levels significantly (Fig. 7b,c). Therefore, only the RHT 
treatment group displayed the enhanced protein levels of both cleaved PARP and cleaved caspase 3 necessary to 
indicate apopotosis onset.
To better quantify cell death onset and rule out cell line specificity, both U-87 and U-118MG cells were 
stained with propidium iodide (PI) and its uptake was quanitified via flow cytometery. PI is a DNA-intercalating 
agent that is not inherently cell-permeable and can therefore be used to measure viability as dying cells have 
compromised membrane integrity. Furthermore, to ensure that the decreased viability observed in the HCQ, 
HT and RHT treatment groups were not due to off target effects of HCQ, a novel polymer was designed to pH 
dependently deliver HCQ to lysosomes (Fig. 7c,d). Polypeptide-based pH responsive polymers are well reported 
Figure 7. Cell death is only apparent for RHT treatment in both U-87 and U-118 MG cells. Propidium Iodide 
(PI) uptake quantification for both cell lines is shown in (a) and (b) treated with 50 nM Rapamycin (Rapa), 
50 µM Hydroxychloroquine-polymer (P-HCQ), 250 µM Temozolomide (TMZ), 50 µM (P-HCQ) + TMZ 
(250 µM) (HT) and Rapa (50 nM) + P-HCQ (50 µM) + TMZ (250 µM) (RHT). P-HCQ treated U-118 MG 
cells stained with Lysotrakcer Blue and Nile Red (Scale Bar 5 µM) is shown in (c) as well as overlay between 
Lysotracker Blue and Nile red indicated in the enhanced image, confirming that the HCQ-polymer reached 
lysosomes (Scale Bar 1 µM). (d) Schematic representation of the release of the (acid labile) β-thiopropionate 
linked hydroxychloroquine drug from the poly(N-vinylpyrrolidone-block-(cysteine-co-glycine)) [PVP-b-rPp] 
(Pp = polypeptide). *p < 0.05, n = 3. All error bars, ± SEM.
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as nanocarriers for bioactive molecules23,30. Hence we prepared a new nanocarrier, where hydroxychloroquine 
is covalently attached via an acid-labile β-thiopropionate bond. The acid-labile β-thiopropionate linker has been 
employed for nonpolypeptide (conventional polymers) based pH responsive polymers and can release drugs or 
bioactive molecules near endosomal pH (6 to 5)31,32.
PI viability assays indicate that the HCQ-polymer did not significantly enhance cell death when treated in 
isolation (50 µM for 6 h), although when used in combination with rapamycin and TMZ a marked increase in cell 
death for the RHT treatment group was observed (Figs 6 and 7). These results correlate well with the decreased 
reductive capacity seen in the initial WST-1 assays (Fig. 1a) and the increased presence of apoptotic proteins 
(Fig. 6a–c).
Lastly, to assess the clinical translatability of these findings, the RHT treatment regimen was compared to 
chemotherapeutic treatment in a 3D tumour spheroid model. It has been established previously that cancer sphe-
roids display considerably more resistance to chemotherapy than monolayer cultures33. Indeed, we found that 
staining U-87 and U-118 spheroids with PI using the same rapamycin, HCQ and TMZ concentrations as for their 
2D counterparts revealed no significant increase in signal intensity or sphere size following the RHT regime. 
However extending the treatment duration for both rapamycin and HCQ to 24 hours (500 nM and 500uM respec-
tively) and TMZ treatment to 72 hours (1 mM) revealed enhanced spheroid cell death and decreased size (Fig. 8).
Discussion
The present study attempted to elucidate whether autophagy modulation would impair GBM metabolism to the 
extent of initiating cell death. Combining autophagy induction with subsequent inhibition was hypothesised to 
debilitate glioma metabolism most prominently in terms of ETS and OXPHOS capacities and mitochondrial 
fission and fusion functionality. We have shown that chemotherapeutic resistance can be overcome through care-
fully coordinated autophagy modulation consisting of both induction and inhibition periods. Importantly, robust 
changes in autophagic degradation activity resulted in the distinct alteration of mitochondrial OXPHOS capacity.
Enhanced degradation through autophagy and complex I linked OXPHOS was observed in response to TMZ 
treatment, indicating that autophagy and mitochondrial respiration is essential for GBM survival under condi-
tions of cytotoxic stress. Given that protein extraction occurred at a single time point, regardless of the rate of 
autophagic degradation, the decrease in initial LC3-II expression following TMZ treatment is representative of 
an already enhanced flux and not necessarily a decrease in autophagosome production34. This is supported by the 
significant increase in LC3-II expression caused by Baf treatment, indicative of an increase in autophagic flux. 
The robust response in LC3-II accumulation following HT treatment strengthens the notion that TMZ enhanced 
autophagic flux (Fig. 1). It has previously been hypothesize that an increased degradative activity enhances 
Figure 8. Assessment of 3D spheroid viability and topology changes under modified TMZ and RHT treatment. 
U-118MG spheroids stained with Hoescht (blue signal) and propidium iodide (PI) are shown in (a) and (b). PI 
Fluorescence intensity for (c) U-118MG spheroids and (e) U-87 spheroids and the outer perimeter of spheroids 
are shown in (d) for U-118MG spheroids and (f) for U-87 spheroids. Treatments consisted of 1 mM TMZ over 
72 hours or 500 nM Rapamycin for 24 hours followed by 500 µM P-HCQ for 24 hours followed by 1 mM TMZ 
for 72 hours (RHT). *p < 0.05 vs Control, #p < 0.05 vs TMZ, n = 8. Scale Bar 100 µM.
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the availability of autophagy derived substrates, serving as an adaptive response to meet cellular metabolic 
demands7,35. Therefore, in the present study, lysosomal deacidification occurred prior to chemotherapy mediated 
autophagy induction, rendering autophagolysosomes with impaired degradative ability. In addition, our results 
revealed that enhanced autophagosomal flux induced by Rapamycin exacerbates this effect. By increasing the 
autophagosomal pool size prior to lysosomal deacidification (RHT) it is possible that autophagosome production 
was enhanced beyond maximal capacity, rendering the TMZ response ineffective (Figs 1 and 4).
To elucidate whether mitochondrial bioenergetics were indeed affected by autophagy modulation, the mito-
chondrial phenotype was assessed in terms of its fission and fusion dynamics. The regulation of both fission 
and fusion events have recently been implicated in metabolic efficiency17,18. In our study, a gradual loss of sig-
nal intensity was observed over time for cells under control conditions indicative of a highly motile network 
(Fig. 2). Linear regression through these slopes indicate significantly slower singal dissipation in all treatment 
groups, which was further exacerbated by ATG5 siRNA knockdown (Fig. 2, Supplementary Fig. 2) in both cell 
lines tested. Importantly, unaltered mitofusin protein expression (MFN1 and MFN2) was observed for treatment 
groups that displayed the least amount of connectivity, indicating that outer membrane fusion was not impaired 
(Fig. 5a,b,e), in the U-118 MG cell line at least. Similarly, DRP1 protein levels were not enhanced in these groups 
(HCQ and TMZ), indicating that enhanced fission was not solely responsible for enhanced fragmentation 
(Fig. 5d,e). However, decreased OPA1 protein levels were observed in fragmented and intermediately connected 
networks, indicating that diminished inner membrane fusion resulted in incomplete fusion (Fig. 5a,e). Therefore, 
loss of OPA1 protein levels proved a better indicator of decreased network connectivity than a decrease in DRP1 
protein levels, suggesting that decreased connectivity was more likely attributable to decreased inner membrane 
fusion and not increased fission. In this regard, RHT treatment caused a significant decrease in both OPA1 and 
DRP1 expression (Fig. 5), indicating that decreased fission regulation altered morphological distribution, given 
that larger and more individual clusters were observed in RHT treated cells compared to TMZ and HT (Fig. 3d).
Extensive investigation has recently been conducted on the involvement of fission and fusion proteins in 
metabolic sensing and mitochondrial efficiency. Mishra et al. (2014) have reported that mouse embryonic fibro-
blast (MEF) cells devoid of MFN1 did not decrease their OXPHOS capacity17. However, OPA1 cleavage has been 
shown to be affected by altered OXPHOS requirements, suggesting that inner membrane fusion is more critical 
to electron transport chain efficiency than outer membrane fusion17. Recent observations revealed that the fission 
regulator, DRP1, is of equal importance, as silencing DRP1 impaired growth, decreased oxygen consumption and 
induced apoptosis in brain tumour initiating cells (BTICs)18. Furthermore, AMPK activation was shown in BTICs 
under these conditions, indicating that impaired DRP1 expression can lead to metabolic stress in cancer cells18. 
Functionally, fragmented mitochondrial networks have been observed in cell types with defective OXPHOS36–38. 
However, OXPHOS impaired primary human fibroblasts also display no apparent morphological changes38–40. 
Contrary to earlier studies, increased fragmentation was not associated with decreased respiratory capacity41. In 
fact, we have shown that OXPHOS capacity remained unaltered in HCQ treated cells that displayed the largest 
amount of fragmentation (Fig. 4). Surprisingly, our data indicate that an increase in OXPHOS, as observed in 
TMZ treated cells, can indeed be associated with decreased mitochondrial connectivity (Figs 3 and 4). Therefore, 
it is possible that mitochondrial fragmentation served as an early adaptive mechanism to chemotherapy in glioma 
cells and highlights the need for further investigation into mitochondrial spatiotemporal changes in this scenario.
MFN1 and MFN2 expression remained unaltered in OXPHOS capable treatment groups, although RHT 
treated cells presented with decreased MFN1 and MFN2 expression (Fig. 5). In accordance with recent literature, 
decreased OPA1 expression was associated with impaired ETS capacity17. DRP1 expression also remained unal-
tered for the Rapamycin, HCQ and HT treatment groups (Fig. 5). Although network fragmentation was observed 
following HCQ, TMZ and HT treatment, these groups displayed sufficient OXPHOS capacity, strengthening the 
case for DRP1 as an important metabolic regulator (Figs. 4 and 5). Consequently, the decreased OXPHOS and 
ETC capacities observed in the RHT treated cells supports this notion. Furthermore, impaired autophagic activity 
was associated with decreased lactate production (Fig. 5). Importantly, U-118MG cells that displayed diminished 
OXPHOS and glycolysis were also found to have enhanced cleaved caspase 3 and cleaved PARP protein levels. 
This indicates that cells were metabolically compromised to the extent of inducing apoptotic cell death. In this 
regard, it has been shown that following MOMP, caspase 3 is capable of cleaving the p75 subunit of complex I, 
decreasing its respiratory efficiency in HeLa cells42. Our results support these findings, as an increase in caspase3 
and decrease in complex I linked OXPHOS was observed for the RHT treatment group. Increased PI uptake in 
both U-87 and U-118 cell lines and 3D spheroid models under RHT treatment further confirmed increased cell 
death sensitization through coordinated autophagy modulation (Fig. 8).
Clinical trials have been conducted to assess the combination of HCQ with TMZ with only stable disease state 
achieved9. However, a more potent inhibitor of autophagy, metformin, has shown great promise in reducing glio-
blastoma chemoresistance both in vitro and in viuvo, suggesting that upstream inhibition of autophagy has greater 
anti-cancer properties than late stage inhibitors such as HCQ43. In this regard, we have shown that by attenuating 
the release mechanism of HCQ, late stage autophagy inhibiton can still impair tumour viability in combination 
with TMZ. Furthermore, given that the flux dependent nature of autophagy is rarely taken into account when 
determining modulator dosages in cancer patients, the possibility exists that the difference in tumour autophagic 
flux and healthy tissue offsets the efficiency of dose escalation studies. This is evident in the recent clinical trial 
combining temsirolimus (TEM), a rapamycin analog, and HCQ, where only stable disease state was reached in 
patients with advanced solid tumours44.
In the current study, we have shown that disruption of the autophagic system is possible through coordi-
nated modulation with drug concentrations based on relative flux assessments in addition to toxicitiy assays. 
We have demonstrated that such modulation was effective in impairing the ability of GBM cells to evade 
chemotherapy-induced cell death. Impaired autophagic degradation resulted in decreased mitochondrial res-
piration, with OXPHOS being impaired to a greater extent in intermediately fragmented rather than completely 
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fragmented networks. These findings may be of clinical importance and highlights the dependency of GBM sur-
vival on the interaction between the autophagic system and mitochondrial bioenergetics. Future work is required 
to enhance clinical translation of coordinated autophagy modulation as a clinical therapeutic intervention for 
GBM.
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